Biofrontera Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Biofrontera reported Q2 2026 net product revenue of $12.0M (up 32.9% YoY from $9.0M), with gross margin improving 920 basis points to 80% (vs. 71% prior year), driven by a lower cost structure from the October 2025 strategic transaction with Biofrontera AG. Net loss narrowed to $0.6M (−$0.05/share) from $5.3M (−$0.57/share); Adjusted EBITDA improved to −$0.2M from −$5.1M. H1 2026 revenue grew 25.4% to $22.1M; operating cash burn fell 76% to $1.7M. Cash position: $4.7M as of June 30, 2026; convertible notes of $4.6M mature November 2027. sBCC (superficial basal cell carcinoma) PDUFA decision expected late September 2026.
Why this rating
Strong revenue growth (33%), margin expansion (920bp), EBITDA near breakeven, and cash burn reduction are operationally material. However, absolute H1 revenue $22.1M and remaining cash $4.7M represent ~3.2x and 68% of $6.9M market cap—tight liquidity despite improvement. sBCC approval is a pipeline catalyst. Not transformational but tangible operational progress for a micro-cap.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.